Arvinas (ARVN) Current Assets (2017 - 2026)
Arvinas (ARVN) posted quarterly Current Assets of $630.7 million for Q1 2026, down 35.62% year-over-year from $979.7 million in Q1 2025, and down 9.99% quarter-over-quarter from $700.7 million in Q4 2025.
Arvinas (ARVN) Current Assets (2017 - 2026) Analysis & Trends
Arvinas' Current Assets history runs 10 years deep, the most recent figure standing at $630.7 million for Q1 2026.
- In Q1 2026, Current Assets fell 35.62% year-over-year to $630.7 million; the TTM figure through Mar 2026 stood at $630.7 million (down 35.62% YoY), while the FY2025 annual figure was $700.7 million, down 34.35% from the prior year.
- Current Assets for Q1 2026 stood at $630.7 million, down from $700.7 million in the prior quarter.
- The five-year high for Current Assets was $1.5 billion in Q1 2022, with the low at $630.7 million in Q1 2026.
- The 5-year median for Current Assets is $1.1 billion (2023), against an average of $1.1 billion.
- The sharpest annual moves came in 2022 and 2026: Current Assets surged 119.26% in 2022, then slumped 35.62% in 2026.
- Arvinas' Current Assets stood at $1.2 billion in 2022, then advanced by 3.23% to $1.3 billion in 2023, then declined by 16.63% to $1.1 billion in 2024, then plunged by 34.35% to $700.7 million in 2025, then declined by 9.99% to $630.7 million in 2026.
- Business Quant data shows ARVN's Current Assets at $630.7 million in Q1 2026, $700.7 million in Q4 2025, and $826.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 652.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 652.20 Mn |
| Mar 31, 2026 | 630.70 Mn |
| Dec 31, 2025 | 700.70 Mn |
| Sep 30, 2025 | 826.30 Mn |
| Jun 30, 2025 | 889.50 Mn |
| Mar 31, 2025 | 979.70 Mn |
| Dec 31, 2024 | 1.07 Bn |
| Sep 30, 2024 | 1.15 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.19 Bn |
| Dec 31, 2023 | 1.28 Bn |
| Sep 30, 2023 | 1.03 Bn |
| Jun 30, 2023 | 1.06 Bn |
| Mar 31, 2023 | 1.15 Bn |
| Dec 31, 2022 | 1.24 Bn |
| Sep 30, 2022 | 1.30 Bn |
| Jun 30, 2022 | 1.38 Bn |
| Mar 31, 2022 | 1.46 Bn |
| Dec 31, 2021 | 1.55 Bn |
| Sep 30, 2021 | 1.58 Bn |